CELLDEX THERAPEUTICS INC (CLDX)
US15117B2025 - Common Stock
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.42M 107.84% | 4.65M -37.33% | 2.36M -49.25% | 2.669M 13.09% | ||||||||
| EBITDA YoY % growth | -41.42M 14.37% | -64.67M -56.13% | -97.33M -50.50% | -137.7M -41.48% | N/A | N/A | N/A | N/A | N/A | N/A | ||
| EBIT YoY % growth | -45.35M 14.80% | -67.74M -49.37% | -100.23M -47.96% | -136.799M -36.49% | ||||||||
| Operating Margin | -611.19% | -1,456.77% | -4,247.03% | -5,125.48% | ||||||||
| EPS YoY % growth | -2.14 41.05% | -1.64 23.36% | -2.21 -34.76% | -2.69 -21.58% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.82 -47.01% | ||||
| Revenue Q2Q % growth | 935.003K -41.93% | ||||
| EBITDA Q2Q % growth | -43.146M | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -43.676M -56.60% |
All data in USD
| Period | Reported | Estimate | Difference | Suprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | -0.81 -42.11% | -0.69 | -0.12 | -17.03% |
| Q2 2023 Q2Q % growth | -0.65 -10.17% | -0.68 | 0.03 | 4.41% |
| Q1 2023 Q2Q % growth | -0.62 -26.53% | -0.64 | 0.02 | 3.82% |
| Q4 2022 Q2Q % growth | -0.56 -30.23% | -0.60 | 0.04 | 6.95% |
| Q3 2022 Q2Q % growth | -0.57 -26.67% | -0.59 | 0.02 | 3.09% |
| Q2 2022 Q2Q % growth | -0.59 -73.53% | -0.52 | -0.07 | -13.42% |
| Q1 2022 Q2Q % growth | -0.49 -16.67% | -0.46 | -0.03 | -5.81% |
| Q4 2021 Q2Q % growth | -0.43 21.82% | -0.43 | 0.00 | -1.18% |
| Period | Reported | Estimate | Difference | Suprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 1.52M 270.73% | 586.837K | 933.163K | 159.02% |
| Q2 2023 Q2Q % growth | 270K 68.75% | 538.56K | -268.56K | -49.87% |
| Q1 2023 Q2Q % growth | 970K 470.59% | 418.2K | 551.8K | 131.95% |
| Q4 2022 Q2Q % growth | 1.61M 387.88% | 269.28K | 1.341M | 497.89% |
| Q3 2022 Q2Q % growth | 410K 173.33% | 367.2K | 42.8K | 11.66% |
| Q2 2022 Q2Q % growth | 160K -95.40% | 408K | -248K | -60.78% |
| Q1 2022 Q2Q % growth | 170K -75.36% | 571.2K | -401.2K | -70.24% |
| Q4 2021 Q2Q % growth | 330K -91.29% | 1.057M | -727K | -68.78% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -17.95% | -16.69% | 0% | 1.4% |
| Revenue | 3.97% | 58.05% | 0% | 0.11% |